Go offline with the Player FM app!
Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
Manage episode 429527393 series 2592278
In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.
Featured Articles:
- Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
- Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
- Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation
270 episodes
Manage episode 429527393 series 2592278
In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.
Featured Articles:
- Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial
- Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT
- Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation
270 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.